BioCentury | Jun 18, 2019
Financial News

June 18 Financial Quick Takes: Biohaven sinks on fund-raising news; plus IPO trio sets terms

Amid buyout rumors, Biohaven proposes follow-on Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) lost $13.54 (24%) to $43.83 on Tuesday, shedding more than half a billion dollars in market cap, after it proposed to raise $300...
BioCentury | Sep 28, 2018
Financial News

Sutro raises about $95M total in IPO, private placement

Sutro Biopharma Inc. (NASDAQ:STRO) raised $85 million late Sept. 26 through the sale of 5.7 million shares at $15 in an upsized IPO underwritten by Cowen, Piper Jaffray, JMP Securities and Wedbush PacGrow. The price,...
BioCentury | Sep 27, 2018
Financial News

Trio of IPOs price: Arvinas, Sutro, Urovant

Arvinas Inc. (NASDAQ:ARVN), Sutro Biopharma Inc. (NASDAQ:STRO) and Urovant Sciences Ltd. (NASDAQ:UROV) each priced IPOs late Wednesday, raising a total of $345 million. On Thursday, Arvinas gained $0.05 to $16, and Sutro was up $0.20...
BioCentury | Jun 1, 2018
Financial News

Scholar Rock raises $75M IPO

Scholar Rock Holding Corp. (NASDAQ:SRRK) raised $75 million on May 23 through the sale of 5.4 million shares at $14 in an IPO. Jefferies, Cowen, BMO Capital Markets and Wedbush PacGrow underwrote the deal. Scholar...
BioCentury | May 24, 2018
Financial News

Scholar Rock shares rise after IPO

Scholar Rock Holding Corp. (NASDAQ:SRRK) gained $1.50 (11%) to $15.50 in its first day of trading Thursday after raising $75 million through the sale of 5.4 million shares at $14 in an IPO. Jefferies, Cowen,...
BioCentury | May 18, 2018
Financial News

Kiniksa, Scholar Rock set IPO price ranges

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) and Scholar Rock Holding Corp. (Cambridge, Mass.) each set price ranges on May 14 for their respective NASDAQ IPOs. Kiniksa now plans to sell 7 million shares at $17 to...
BioCentury | May 14, 2018
Financial News

Kiniksa, Scholar Rock set IPO price ranges

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) and Scholar Rock Holding Corp. (Cambridge, Mass.) each set price ranges on Monday for their respective NASDAQ IPOs. Kiniksa now plans to sell 7 million shares at $17 to $19...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...or BRCA2 mutations Submit reg apps in U.S. and Japan 4Q17 Audentes Therapeutics Inc. (NASDAQ:BOLD) AT342...
BioCentury | Apr 19, 2017
Financial News

Agios, Audentes price follow-ons

...diseases, including a trial of AT132 to treat X-linked myotubular myopathy and a study of AT342...
...4Q17. AT132 is an adeno-associated viral serotype8 (AAV8) vector delivering the myotubularin 1 (MTM1) gene. AT342...
...polypeptide A1 (UGT1A1) gene. Both candidates have Orphan Drug designation in the U.S. and EU. Chris Lieu AG-120 AT132 AT342 enasidenib Agios...
BioCentury | Jul 20, 2016
Top Story

Audentes inches up after pricing $75M IPO

...IND this quarter for AT982 (formerly AT002 ) to treat Pompe's disease, next quarter for AT342...
...adeno-associated viral serotype 9 (AAV9) vector carrying the acid alpha glucosidase ( GAA ) gene. AT342...
Items per page:
1 - 10 of 12